相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent developments in adjunct therapies for type 1 diabetes
Joseph G. G. Timmons et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud et al.
NATURE REVIEWS ENDOCRINOLOGY (2023)
Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation
S. Elise Lawrence et al.
CLINICAL TRANSPLANTATION (2023)
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience
Ana Palanca et al.
DIABETES CARE (2022)
Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes
Signe Schmidt et al.
DIABETES OBESITY & METABOLISM (2022)
INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA)
Jukka Kero et al.
DIABETIC MEDICINE (2022)
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETOLOGIA (2022)
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study br
Gabriel A. Gregory et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Report of An NIDDK Workshop in October 2021
Elizabeth R. Seaquist et al.
DIABETES CARE (2022)
Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes
Anne-Marie Wegeberg et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2021)
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
Matthias von Herrath et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Obesity in people living with type 1 diabetes
Bart Van der Schueren et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials
Thomas F. Dejgaard et al.
DIABETES OBESITY & METABOLISM (2021)
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial
Thomas F. Dejgaard et al.
DIABETES OBESITY & METABOLISM (2020)
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study
Karen E. Elkind-Hirsch et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss
Husam Ghanim et al.
DIABETES OBESITY & METABOLISM (2020)
Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials
Awadhesh Kumar Singh et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
Nicklas J. Johansen et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
Hiroyuki Uchinuma et al.
BMC ENDOCRINE DISORDERS (2020)
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Kevan C. Herold et al.
DIABETES OBESITY & METABOLISM (2020)
Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients
Chitrabhanu Ballav et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2020)
SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Birgit Janssens et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2020)
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
Thomas Danne et al.
DIABETES CARE (2019)
Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy
Christina Brock et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
Simeon I. Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus
L. -l. Jiang et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes
Marie-Christine Dube et al.
DIABETES OBESITY & METABOLISM (2018)
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
John R. Petrie et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebocontrolled, double-blind, parallel-group study
Christian S. Frandsen et al.
DIABETES OBESITY & METABOLISM (2017)
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Bo Ahren et al.
DIABETES CARE (2016)
Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks
Nitesh D. Kuhadiya et al.
DIABETES CARE (2016)
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
Chantal Mathieu et al.
DIABETES CARE (2016)
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Thomas Fremming Dejgaard et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
Christian S. Frandsen et al.
DIABETES CARE (2015)
Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial
Signe H. Ostoft et al.
DIABETES CARE (2014)
Glucagon-Like Peptide-1 Protects Human Islets against Cytokine-Mediated β-Cell Dysfunction and Death: A Proteomic Study of the Pathways Involved
Dieter Rondas et al.
JOURNAL OF PROTEOME RESEARCH (2013)
Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans
Daniel H. van Raalte et al.
DIABETES CARE (2011)
分享论文
